These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 16076267)

  • 1. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ; Lip GY
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran: a new oral anticoagulant.
    Hrebickova L; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(6):397-408. PubMed ID: 14633322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New possibilities in anticoagulant management of atrial fibrillation.
    Waldo AL
    Rev Cardiovasc Med; 2004; 5 Suppl 5():S30-8. PubMed ID: 15619613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
    Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
    Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New perspectives for anticoagulation in non-rheumatic atrial fibrillation: oral antithrombins].
    Scardi S; Giansante C
    Ital Heart J Suppl; 2004 Sep; 5(9):705-11. PubMed ID: 15568608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).
    Halperin JL;
    Am Heart J; 2003 Sep; 146(3):431-8. PubMed ID: 12947359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trials and tribulations of non-inferiority: the ximelagatran experience.
    Kaul S; Diamond GA; Weintraub WS
    J Am Coll Cardiol; 2005 Dec; 46(11):1986-95. PubMed ID: 16325029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics.
    Ezekowitz MD
    Am Heart Hosp J; 2004; 2(4 Suppl 1):31-5. PubMed ID: 15539973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
    McCullough PA; Dorrell KA; Sandberg KR; Yerkey MW
    Rev Cardiovasc Med; 2004; 5(2):99-103. PubMed ID: 15184843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombotic therapies for stroke prevention in atrial fibrillation.
    Economides Muñoz C; Singh BN
    Minerva Cardioangiol; 2004 Apr; 52(2):125-39. PubMed ID: 15194994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ximelagatran in prevention of cardiovascular events.
    Molckovsky D; Boucher M
    Issues Emerg Health Technol; 2004 Nov; (62):1-4. PubMed ID: 15565751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [SPORTIF III and V trials: a major breakthrough for long-term oral anticoagulation].
    Kulbertus H
    Rev Med Liege; 2003 Dec; 58(12):770-3. PubMed ID: 14978854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.